https://www.xatakaciencia.com/medicina/valneva-pfizer-estan-desarrollando-nueva-vacuna-que-evitaria-que-garrapatas-transmitieran-enfermedad-lyme
Jan 4, 2022 - La enfermedad de Lyme es una infección bacteriana que se contrae por la picadura de una garrapata infectada. Al principio, la enfermedad de Lyme...
valnevapfizerunanuevaque
https://www.beaboss.fr/Thematique/start-up-1271/levee-fonds-2074/Breves/Valneva-leve-61-millions-d-euros-pour-financer-ses-vaccins-463546.htm
Sep 13, 2024 - L'entreprise Valneva, spécialisée dans le développement et la commercialisation de vaccins, lève 61 millions d'euros. Cette opération permettra...
valnevamillionseurospourses
https://www.pharmaceutical-technology.com/news/valneva-trims-rd-footprint-by-shutting-french-facility/
Nov 27, 2025 - The consolidation comes a week after the vaccine specialist downgraded its 2025 guidance.
valnevatrimsampfootprintshutting
https://vaccinenation.org/technology/valneva-and-limmatech-secure-shigella-vaccine-fast-track/
Oct 17, 2024 - Valneva and LimmaTech Biologics announced in October 2024 that they have been granted Fast Track designation by the United States FDA for Shigella4V
fast trackvalnevasecurevaccine
https://www.biopharmadive.com/news/pfizer-valneva-lyme-disease-vaccine-phase-3/629200/
The experimental vaccine is the most advanced candidate for the tick-borne disease and, if successful, would be the first to reach the market since withdrawal...
next steplyme diseasepfizervalnevatake
https://www.tradingsat.com/valneva-FR0004056851/actualites/valneva-de-nouveaux-resultats-cliniques-positifs-sur-son-vaccin-contre-la-maladie-de-lyme-portent-valneva-en-bourse-1151397.html
Nov 26, 2025 - (BFM Bourse) - Le spécialiste des vaccins contre les maladies infectieuses a dévoilé des résultats cliniques intermédiaires positifs pour son candidat …
valnevadenouveauxsurson
https://www.clinicaltrialsarena.com/news/valneva-lyme-vaccine/
Nov 27, 2025 - Valneva has reported final safety and immunogenicity findings from the randomised Phase II trial, VLA15-221, assessing the Lyme disease vaccine candidate VLA15.
final resultsphase iilyme diseasevalnevareports
https://www.4investors.de/nachrichten/boerse.php?sektion=stock&ID=187140
Valneva SE bündelt seine französischen Aktivitäten am Standort Lyon und verlegt die Forschungs- und Entwicklungsaktivitäten nach Wien.
valnevastandorteundforschungwien
https://valneva.com/
May 26, 2025 - We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs.
valneva